Andrew Siedlecki, MD
Ophthalmology · Williamsville, NYNPI 1588028609
Payments from drug & device makers
Across 194 payments — averaging $34.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$2K
- AbbVie$882
- Glaukos Corporation$722
- Rayner Intraocular Lenses Limited$711
- Johnson & Johnson Surgical Vision, Inc.$399
- Harrow Eye, LLC$332
- plus $1K from 18 others
What the payments were for
- Food & beverage$6,679100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 64 | $2,245 |
| AbbVie(2 entities) | 26 | $882 |
| Glaukos Corporation | 10 | $722 |
| Rayner Intraocular Lenses Limited | 16 | $711 |
| Johnson & Johnson Surgical Vision, Inc. | 10 | $399 |
| Harrow Eye, LLC | 11 | $332 |
| Sun Pharmaceutical Industries Inc. | 14 | $279 |
| Rxsight Inc | 2 | $157 |
| Regeneron | 1 | $130 |
| Aerie Pharmaceuticals, Inc. | 6 | $102 |
| Oyster Point Pharma, Inc. | 5 | $102 |
| Bausch & Lomb Americas Inc. | 5 | $96 |
| Ivantis, Inc | 1 | $85 |
| Amgen(2 entities) | 5 | $83 |
| Kala Pharmaceuticals, Inc. | 3 | $66 |
| Ocular Therapeutix, Inc. | 3 | $63 |
| Astellas Pharma US Inc | 2 | $55 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $44 |
| Eyevance Pharmaceuticals LLC | 2 | $26 |
| Thea Pharma Inc. | 1 | $25 |
| Sight Sciences, Inc. | 1 | $23 |
| Regeneron Healthcare Solutions, Inc. | 1 | $22 |
| Mallinckrodt Hospital Products Inc. | 1 | $17 |
| Novartis | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OMIDRIA$397
- RayOne EMV$397
- RayOne Spheric$397
- RayOne Aspheric$397
- iDoseTR$392
- LenSx$391
- OZURDEX$236
- RXSIGHT CONTACT LENS$137
- RXSIGHT INJECTOR CARTRIDGE$137
- RXSIGHT INJECTOR HANDPIECE$137
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$137
- LIGHT ADJUSTABLE LENS (LAL)$137
- EYLEA$130
- ARGOS$127
- Clareon PanOptix Pro$125
- Tecnis IOL$122
- VERITAS Vision System$120
- Tecnis Simplicity$120
- Clareon$119
- AcrySof IQ PanOptix UV IOL$116
How this compares
$6,679 in reported general payments places this provider in the 80th percentile of 1,587 ophthalmology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 324 | $13,015 |
| XiidraLifitegrast | 14 | $10,509 |
| Cyclosporine | 12 | $7,382 |
| LumiganBimatoprost | 13 | $6,294 |
| Prednisolone Acetate | 158 | $5,392 |
| Ketorolac Tromethamine | 271 | $4,376 |
| Latanoprost | 265 | $4,182 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 92 | $2,890 |
| Timolol Maleate | 58 | $2,279 |
| Brimonidine Tartrate | 39 | $1,866 |
| Atropine Sulfate | 41 | $1,422 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 69 | $998 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Xiidra | $96 | $10,50914 claims |
| AbbVieLumigan | $882 | $6,29413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,587 ophthalmology providers in New York.
Other ophthalmology in Williamsville
- Douglas JabsNew York$24.3M
- David RubaltelliBrooklyn$8.9M
- Philip FerroneGreat Neck$5.8M
- Eric DonnenfeldGarden City$2.6M
- Nathan RadcliffeNew York$2.4M
- Glenn StollerRockville Centre$2.1M
- Richard SpaideNew York$1.7M
- Paul HartmanRochester$1.6M
- Jason SlakterNew York$1.2M
- David ChuNew York$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.